codevelopment agreement

Chembio said it will receive funding subject to satisfying milestones to develop a test that leverages its immunoassay platform and hand-held optical analyzer.

Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.

The two organizations will first focus on developing and validating Breath Diagnostics' OneBreath platform for lung cancer.

Group K said that the partners are developing a RT-LAMP system for use at the point of care in resource-limited areas where real-time RT-PCR is not available.

The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.

The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.

The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.

The two companies will initially collaborate on global commercialization of assays that have been developed by LabCorp and its Covance unit.

The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.